UK biotech venture funding rebounded in the second quarter of 2026, reaching a record high while geopolitical uncertainty continued to weigh on initial public offering sentiment. The report describes a fundraising revival alongside increased investor willingness to deploy capital, even as IPO planning remains chilled. For biotech teams preparing for commercialization and clinical milestones, the divergence between VC activity and IPO appetite points to a market that is funding growth stages but still cautious about public exits. That could affect how late-stage companies prioritize financing strategy, deal timing, and whether they seek partnerships instead of public listings. The snapshot suggests risk capital is returning, but liquidity events may still depend on clearer macro conditions and company-specific catalysts.